Literature DB >> 16981668

CALGB/SWOG C80405: A phase III trial of FOLFIRI or FOLFOX with bevacizumab or cetuximab or both for untreated metastatic adenocarcinoma of the colon or rectum.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16981668

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


× No keyword cloud information.
  4 in total

Review 1.  Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.

Authors:  Jean-Baptiste Bachet; Lucie Peuvrel; Claude Bachmeyer; Ziad Reguiai; Pierre A Gourraud; Olivier Bouché; Marc Ychou; Rene J Bensadoun; Brigitte Dreno; Thierry André
Journal:  Oncologist       Date:  2012-03-16

2.  Clinical impact of primary tumor sidedness and sex on unresectable post-recurrence survival in resected pathological stage II-III colorectal cancers: a nationwide multicenter retrospective study.

Authors:  Shinya Abe; Kazushige Kawai; Hiroaki Nozawa; Kazuhito Sasaki; Koji Murono; Shigenobu Emoto; Tsuyoshi Ozawa; Yuichiro Yokoyama; Yuzo Nagai; Hiroyuki Anzai; Hirofumi Sonoda; Shinichi Yamauchi; Kenichi Sugihara; Soichiro Ishihara
Journal:  BMC Cancer       Date:  2022-05-02       Impact factor: 4.638

3.  Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study.

Authors:  Chieh-Lin Jerry Teng; Chen-Yu Wang; Yi-Huei Chen; Ching-Heng Lin; Wen-Li Hwang
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

4.  Is the Location of the Tumor Another Prognostic Factor for Patients With Colon Cancer?

Authors:  Myung-Kyu Jung; Ui Sup Shin; Young-Jun Ki; Yong-Bae Kim; Sun-Mi Moon; Se-Jin Sung
Journal:  Ann Coloproctol       Date:  2017-12-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.